Clinical Trial

A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-04-24
notable Trial sites expanded: 1 -> 6 locations 2026-04-02
Trial Details
NCT Number NCT07390383
Lead Sponsor Nanjing Leads Biolabs Co.,Ltd
Collaborators: Peking University Cancer Hospital & Institute
Conditions Advanced Solid Tumour
Enrollment 110 participants
Start Date 2026-04-13
Primary Completion 2028-05-30 (estimated)
Study Completion 2028-05-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-13